Amneal Pharmaceuticals, Inc. AMRX Specialty — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — research and development expense?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — research and development expense of $5.1M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — research and development expense changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — research and development expense decreased by 43.7% year-over-year, from $9.06M to $5.1M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — research and development expense?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — research and development expense has grown at a -8.7% compound annual growth rate (CAGR), from $43.48M to $30.16M.
- What does specialty — research and development expense mean?
- Measures the investment in scientific research, clinical trials, and product development aimed at expanding or improving the specialty pharmaceutical product pipeline. This metric reflects the company's commitment to long-term innovation and future revenue potential. It is a key indicator of the segment's ability to sustain a competitive advantage through new therapeutic offerings.